Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256859 | 0.93 | CYP2C9 (0.46) | PPARDPPARANR1H2NR1H3RXRA | |
| SCHEMBL2256128 | 0.89 | RXRA (0.47) | PPARDPPARANR1H2NR1H3RXRA | |
| SCHEMBL2260114 | 0.88 | RXRA (0.49) | PPARDPPARANR1H2NR1H3RXRA | |
| SCHEMBL2259001 | 0.85 | NR4A2 (0.46) | NR1H2NR1H3RXRATRPV1 | |
| SCHEMBL2258608 | 0.85 | RXRA (0.49) | PPARDPPARANR1H2NR1H3RXRA | |
| SCHEMBL2260221 | 0.84 | NR1H4 (0.49) | PPARDPPARANR1H2NR1H3RXRA | |
| SCHEMBL2257420 | 0.84 | NR1H2 (0.50) | NR1H2NR1H3RXRATRPV1 | |
| SCHEMBL2257733 | 0.84 | GAA (0.42) | NR1H2NR1H3RXRATRPV1 | |
| SCHEMBL3218700 | 0.84 | P2RY1 (0.44) | NR1H2NR1H3RXRATRPV1 | |
| SCHEMBL2256753 | 0.83 | NR1H4 (0.49) | NR1H2NR1H3RXRANR1H4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | PPARD 57/4885PPARA 77/4885NR1H2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.